Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

Goldman Sachs updated its price target on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN) shares to GBP150.67, down from GBP155.58, while reaffirming a Buy rating on the stock. The adjustment follows a ...

Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super ...

DAVENPORT & Co LLC decreased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & ...

How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...